CAMBRIDGE, Mass., April 20 /PRNewswire/ -- Xennex Inc. (Xennex) announced today that it is collaborating with Satoris Inc. (Satoris) and has provided Satoris with access to GeneCards(R) and associated proprietary tools, including GeneAlaCart and early access to input from the advanced prototype of GeneCards(R) version 3.0, which is in advanced stages of development. Satoris is utilizing GeneCards and the related technology for research related to its identification and characterization of protein biomarkers associated with neurological disease such as Alzheimer's, Parkinson's, Multiple Sclerosis, and Diabetic Neuropathy to create new diagnostic tools for earlier, better healthcare decisions.
"We welcome the opportunity to collaborate with Xennex and utilize the newest available GeneCards tools in the further characterization of plasma protein biomarkers we have identified in our studies as being significant in neurodegenerative disease process," said Cris McReynolds, President & CEO of Satoris.
Dr. David Warshawsky, President & CEO of Xennex, stated: "We are very pleased that we can offer Satoris with our most advanced tools and the latest GeneCards developments to assist in their work. Satoris' work is of great potential for improved diagnosis and treatment of devastating conditions and we are delighted that GeneCards is assisting in this important cutting-edge research."
GeneCards(R) (http://www.genecards.org) is a searchable, integrated database of human genes that provides concise genomic, proteomic, transcriptomic, genetic and functional information on all known and predicted human genes. Information featured in GeneCards includes orthologies, disease relationships, mutations and SNPs, gene expression, gene function, pathways, protein-protein interactions, related drugs & compounds and direct links to cutting-edge research reagents and tools such as antibodies, recombinant proteins, clones, expression assays and RNAi reagents. GeneCards was developed over the last 12 years by a world-leading bioinformatics team at the Weizmann Institute of Science in Israel.
Founded in 2003, Xennex Inc. (http://www.xennexinc.com) is a dynamic privately held company that is dedicated to providing Biotechnology, Pharmaceutical and other life sciences companies, as well as organizations dealing with biotechnology intellectual property, the highest level of services and tools to enhance their gene-based research. Xennex' products help such organizations to optimize their efforts to develop innovative medical products and services.
Xennex' customers include many of the world's leading Biotech and Pharmaceutical companies and organizations dealing with intellectual property, located in North America, Europe and Japan. Xennex' products are used in hundreds of commercial and academic organizations by tens of thousands of users around the globe.
Founded in 2003 and based in Redwood City, California, Satoris, Inc. is a molecular diagnostics company focused on developing blood-based tests for Alzheimer's disease. For more information, see http://www.satorisinc.com.
For further information, please contact: Xennex Inc. David Warshawsky, Ph.D. Chief Executive Officer Tel: +1 617 497 7774 email@example.com
|SOURCE Xennex Inc.|
Copyright©2009 PR Newswire.
All rights reserved